Pharmaceuticals, Biotechnology and Life Sciences
Oxford BioDynamics and its scientific advisory panel member, Dr Claudio Carini will be joining Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium as a member of the Cancer, Inflammation & Immunity, and Neuroscience Steering Committees, the company said Thursday.
A study showed that cannabidiol shows great promise in that it may reduce seizures that are otherwise difficult to control.
Faron Pharmaceuticals has decided to add new names to its board, for which the shareholders will decided in May.
Faron Pharmaceuticals and the University of Birmingham Medical School, have signed an agreement to begin a liver cancer program for clinical testing of Faron’s immuno switch antibody Clevegen.
Circassia Pharmaceuticals’s study of house dust mite allergy immunotherapy phase IIb field study failed to meed its primary endpoint, the company said Tuesday.
Respiratory diseases biopharmaceutical specialist, Verona Pharma said Tuesday that the U.S. Food and Drug Administration has given the green light for the kick-start of a pharmacokinetic (PK) clinical trial in the U.S. for its RPL554 candidate, with the acceptance of an Investigational New Drug application (IND).
DermTech, Inc., a player in non-invasive molecular dermatology, has entered into two collaborations with multi-national pharmaceutical companies,
The legal cannabis market was worth an estimated $6.6 billion in 2016, and is projected to grow at a compound annual growth rate (CAGR) of 16% or reaching more than $24 billion by 2025.
BioMarin Pharmaceutical and Par Pharmaceutical have entered into a settlement agreement that resolves patent litigation in the United States (U.S.) related to BioMarin’s Kuvan 100mg oral tablets and powder for oral solution in 100mg packets.
Innovative UK poured almost a million pounds to a developer of cell therapies including hematopoietic cell replacement therapies, Plasticell.